Protein Summary
May be a survival factor for hippocampal and mesencephalic neurons. The shedded form up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation. This gene encodes a member of the tomoregulin family of transmembrane proteins. This protein has been shown to function as both an oncogene and a tumor suppressor depending on the cellular context and may regulate prostate cancer cell invasion. Multiple soluble forms of this protein have been identified that arise from both an alternative splice variant and ectodomain shedding. Additionally, this gene has been found to be hypermethylated in multiple cancer types. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]
- ENST00000272771
- ENSP00000272771
- ENSG00000144339
- ENST00000392314
- ENSP00000376128
- ENST00000409056
- ENSP00000386871
- HPP1
- TENB2
- TPEF
- TR
- HPP1
- TPEF
- TR-2
- TENB2
- CT120.2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor perturbation | 0.8 | ||
histone modification site profile | 0.77 | ||
cell type or tissue | 0.73 | ||
PubMedID | 0.69 | ||
transcription factor binding site profile | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 79.98 (req: < 5)
Gene RIFs: 39 (req: <= 3)
Antibodies: 312 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 79.98 (req: >= 5)
Gene RIFs: 39 (req: > 3)
Antibodies: 312 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0